# QH101 Cell Therapy Relapsed/Refractory(R/R) Acute Myeloid Leukemia(AML) and Myelodysplastic Syndromes(MDS)

> **NCT07131085** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Anhui Provincial Hospital** · enrollment: 9 (estimated)

## Conditions studied

- MDS
- AML

## Interventions

- **DRUG:** Allogeneic TCR-enhanced γδ T cell(QH101)
- **DRUG:** Fludarabine (FLU)
- **DRUG:** Cyclophosphamide (CTX)

## Key facts

- **NCT ID:** NCT07131085
- **Lead sponsor:** Anhui Provincial Hospital
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-08-15
- **Primary completion:** 2027-12-31
- **Final completion:** 2027-12-31
- **Target enrollment:** 9 (ESTIMATED)
- **Last updated:** 2025-08-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07131085

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07131085, "QH101 Cell Therapy Relapsed/Refractory(R/R) Acute Myeloid Leukemia(AML) and Myelodysplastic Syndromes(MDS)". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT07131085. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*